



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 239 873 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
29.06.2005 Bulletin 2005/26

(51) Int Cl.7: **A61K 38/48, A61P 7/02,**  
**A61P 9/10**

(21) Application number: 00988099.8

(86) International application number:  
PCT/US2000/034143

(22) Date of filing: 15.12.2000

(87) International publication number:  
WO 2001/043765 (21.06.2001 Gazette 2001/25)

### (54) USE OF FIBRINOLYTIC METALLOPROTEINASES FOR THE THERAPEUTIC TREATMENT OF A BLOOD CLOT

VERWENDUNG VON FIBRINOLYTISCHEN METALLPROTEINASEN ZUR BEHANDLUNG VON BLUTGERINSELN

UTILISATION DE METALLOPROTEASES FIBRINOLYTIQUES POUR LE TRAITEMENT DE CAILLOTS SANGUINS

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 17.12.1999 US 466276

(43) Date of publication of application:  
18.09.2002 Bulletin 2002/38

(73) Proprietor: Amgen Inc.,  
Thousand Oaks, California 91320-1799 (US)

(72) Inventor: TOOMBS, Christopher, Francis  
Camarillo, CA 93012 (US)

(74) Representative: Richardson, Kate  
Forrester & Boehmert,  
Pettenkoferstrasse 20-22  
80336 München (DE)

(56) References cited:  
EP-A- 0 323 722 WO-A-01/24817  
WO-A-01/25445 US-A- 4 610 879  
US-A- 5 626 564 US-A- 5 922 322

- MARKLAND FRANCIS S ET AL: "Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis." CIRCULATION, vol. 90, no. 5, 1994, pages 2448-2456, XP001010468 ISSN: 0009-7322 cited in the application
- KANDARPA K ET AL: "FORCEFUL PULSATILE LOCAL INFUSION OF ENZYME ACCELERATES THROMBOLYSIS IN-VIVO EVALUATION OF A NEW DELIVERY SYSTEM" RADIOLOGY, vol. 168, no. 3, 1988, pages 739-744, XP001010478 ISSN: 0033-8419

EP 1 239 873 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**Field of the Invention

5 [0001] This invention relates to the therapeutic use of fibrinolytic metalloproteinases, and more specifically to the use of such agents *in vivo* via localized delivery to vascular thrombi in order to effect clot lysis.

Background of the Invention

10 [0002] Vascular occlusions caused by blood clots such as thrombi and embolisms are serious medical maladies that can become limb or life threatening if not timely treated. Devices and methods have been developed for the treatment and removal of vascular blood clots. By way of illustration, see U.S. Patent No. 4,447,236 (Quinn), issued May 8, 1984; U.S. Patent No. 4,692,139 (Stiles), issued September 8, 1987; U.S. Patent No. 4,755,167 (Thistle et al.), issued July 5, 1988; U.S. Patent No. 5,167,628 (Boyles), issued December 1, 1992; U.S. Patent No. 5,222,941 (Don Michael), issued June 29, 1993; U.S. Patent No. 5,250,034 (Appling et al.), issued October 5, 1993; U.S. Patent No. 5,370,653 (Cragg), issued December 6, 1994; U.S. Patent No. 5,380,273 (Dubrul et al.), issued January 10, 1995; U.S. Patent No. 5,498,236 (Dubrul et al.), issued March 12, 1996; U.S. Patent No. 5,626,564 (Zhan et al.), issued May 6, 1997; U.S. Patent No. 5,709,676 (Alt), issued January 20, 1998; U.S. Patent No. 5,865,178 (Yock), issued February 2, 1999, and WO 90/07352 (published July 12, 1990). Such methods and devices include infusion catheters for delivering thrombolytic or fibrinolytic agents to the blood clot and dissolving it. Infusion catheters are typically used in conjunction with enzymatically active agents that are capable of degrading the fibrin in the clot and thus effectively dissolving the clot. Such enzymes are typically referred to as "thrombolytic" or "fibrinolytic" agents.

15 [0003] Fibrolase is a known fibrinolytic zinc metalloproteinase that was first isolated from the venom of the southern copperhead snake (*Agkistrodon contortrix contortrix*). See Guan et al., Archives of Biochemistry and Biophysics, Volume 289, Number 2, pages 197-207 (1991); Randolph et al., Protein Science, Cambridge University Press (1992), pages 590-600; European Patent Application No. 0 323 722 (Valenzuela et al.), published July 12, 1989; and United States Patent No. 4,610,879 (Markland et al.), issued September 9, 1986. Fibrolase has been shown to be fibrinolytic, and this metalloproteinase has been documented to have proteolytic activity against the fibrinogen  $\alpha$ -chain, with reduced proteolytic cleavage of the  $\beta$ -chain and no activity against the  $\gamma$ -chain of fibrinogen; Ahmed et al., Haemostasis, Volume 20, pages 147-154 (1990). Because fibrin is a principal component of blood clots, the fibrinolytic properties of fibrolase point to its potential as a clot dissolving agent for *in vivo* thrombolytic use; see Markland et al., Circulation, Volume 9, Number 5, pages 2448-2456 (1994), and Ahmed et al., above.

20 [0004] Novel Acting Thrombolytic (NAT) is a modified form of fibrolase that differs from fibrolase in that NAT contains 201 amino acids with an N-terminal sequence of SFPQR, whereas the N-terminal sequence of native fibrolase begins with EQRFPQR and is 203 amino acids in length. The amino-terminal modification was designed to prevent chemical reactions at amino acid residues that were capable of forming a variable quantity of cyclized glutamine (pyroglutamic acid) which have the potential to create lot-to-lot variations in quality and uniformity of the product. Thus, NAT can be viewed as a more stable molecule.

25 [0005] Despite these structural differences, NAT and fibrolase are similar with respect to enzymatic (fibrinolytic) activity. This similarity in biological activity is consistent with data indicating that the active site of the fibrolase molecule spans amino acids 139-159, as described by Manning in Toxicon, Volume 33, pages 1189-1200 (1995), and its predicted location in three-dimensional space is distant from the amino-terminus. The active site of the fibrolase and NAT molecules contains a zinc atom which is complexed by three histidine residues.

30 [0006] Published literature on venom-derived fibrolase has demonstrated its proteolytic activity against fibrinogen at the Lys<sup>413</sup>-Leu<sup>414</sup> site and against the oxidized  $\beta$ -chain of insulin at the Ala<sup>14</sup>-Leu<sup>15</sup> site; Retzlos and Markland, Thrombosis Research, Volume 74, pages 355-367 (1994); Pretzer et al., Pharmaceutical Research, Volume 8, pages 1103-1112 (1991), and Pretzer et al., Pharmaceutical Research, Volume 9, pages 870-877 (1992). NAT has also been determined to have proteolytic activity on these substrates at the same cleavage sites.

35 [0007] In contrast to fibrinolytic metalloproteinases such as fibrolase and NAT, clot lysing agents such as streptokinase, urokinase and tissue-type plasminogen activator (tPA) are plasminogen activators which promote thrombolysis by activation of the endogenous fibrinolytic system. More specifically, plasminogen activators catalyze the conversion of plasminogen into plasmin, a serine protease. Plasmin is capable of cleaving fibrinogen and fibrin at arginyl-lysyl bonds, and it is through the generation of plasmin that the plasminogen activators ultimately effect fibrin degradation and clot lysis. Current commercially available thrombolytic agents are plasminogen activators, such as urokinase, streptokinase or tPA.

40 [0008] Unlike the plasminogen activator class of thrombolytic drugs, fibrinolytic metalloproteinases, such as fibrolase and NAT, do not rely on the endogenous fibrinolytic system (conversion of plasminogen to plasmin). Hence, this class of clot lysing agents can be distinguished from the plasminogen activators by their unique mode of action and are

defined as "direct" fibrinolytic agents.

[0009] Alpha<sub>2</sub>-macroglobulin is a prevalent proteinase inhibitor present in mammalian serum and is one of the largest of the serum proteins (having a molecular weight of 725 kilodaltons). The specificity of alpha<sub>2</sub>-macroglobulin for proteinases is broad, encompassing serine, cysteine, aspartic and metalloproteinase classes. The alpha<sub>2</sub>-macroglobulin molecule is a tetramer of identical subunits that are disulfide bonded in pairs with a non-covalent association of the half molecules.

5 Thus, under reducing conditions, native alpha<sub>2</sub>-macroglobulin can be dissociated into its four monomeric subunits.

[0010] Each subunit of alpha<sub>2</sub>-macroglobulin possesses a region that is very susceptible to proteolytic cleavage (the "bait" region). Proteolysis of the bait region induces a conformational change in alpha<sub>2</sub>-macroglobulin, which entraps the proteinase within the alpha<sub>2</sub>-macroglobulin molecular structure. This process is described in the literature as a "venus fly-trap" interaction. Once the proteinase is entrapped, it is sterically hindered and therefore cannot access its macromolecular substrate.

10 [0011] In addition, a covalent bond can form between alpha<sub>2</sub>-macroglobulin and many of the proteinases that it entraps. As mentioned, entrapment of a proteinase induces a conformational change in the alpha<sub>2</sub>-macroglobulin molecule. It is presumed that upon this conformational change, a thioester bond on the interior of the alpha<sub>2</sub>-macroglobulin molecule becomes reactive and can form a covalent bond with nucleophilic residues (such as lysine) of the entrapped proteinase.

15 Thus, within the general circulation, alpha<sub>2</sub>-macroglobulin can effectively neutralize a variety of proteinases. [0012] Moreover, the conformational change in alpha<sub>2</sub>-macroglobulin brought about by the entrapment of a proteinase results in a form that is recognized by the reticuloendothelial system. Clearance of alpha<sub>2</sub>-macroglobulin-entrapped proteinases is generally described with half-life values in minutes and is believed to occur through the low-density lipoprotein (LDL)-receptor related protein expressed on macrophages, hepatocytes and fibroblasts. For more on alpha<sub>2</sub>-macroglobulin, see Methods in Enzymology, edited by A.J. Barrett, Academic Press, Inc., Philadelphia, (1981), pages 737-754.

20 [0013] Alpha<sub>2</sub>-macroglobulin is capable of forming a macromolecular complex with fibrolase, NAT and other proteinases. Unlike some proteinases that can form a dissociable complex with alpha<sub>2</sub>-macroglobulin, fibrolase and NAT are two examples of fibrinolytic metalloproteinases that form a complex which cannot be dissociated from alpha<sub>2</sub>-macroglobulin under physiologic conditions. When purified human alpha<sub>2</sub>-macroglobulin and NAT, for instance, are incubated together, formation of the complex begins in seconds and is nearly complete within a few minutes. This phenomenon shows that *in vitro* complex formation can be rapid and is suggestive of the potential rapidity of complex formation between alpha<sub>2</sub>-macroglobulin and NAT or other fibrinolytic metalloproteinases *in vivo*.

25 [0014] Although alpha<sub>2</sub>-macroglobulin is one of the major plasma proteins, there is nonetheless a finite quantity of alpha<sub>2</sub>-macroglobulin in the circulation that would be available to bind and neutralize a fibrinolytic metalloproteinase. The alpha<sub>2</sub>-macroglobulin binding capacity is therefore saturable. Once the alpha<sub>2</sub>-macroglobulin binding capacity has been exceeded, the concentration of unbound fibrinolytic metalloproteinase rises proportionally as additional fibrinolytic metalloproteinase is added to the sample.

30 [0015] The presence of alpha<sub>2</sub>-macroglobulin in the general circulation of a patient presents a challenge for the systemic (for example, intravenous) administration of fibrolase, NAT and other fibrinolytic metalloproteinases that are bound up by alpha<sub>2</sub>-macroglobulin in the general blood circulation. Unless the saturable level of innate alpha<sub>2</sub>-macroglobulin is exceeded by the systemically administered dose of such fibrinolytic metalloproteinases, the latter will effectively be neutralized and rendered ineffective for therapeutic purposes.

35 [0016] In one *in vivo* study, conducted in rabbits, the biological effectiveness of venom-derived fibrolase was examined following systemic intravenous administration. Ahmed et al., Haemostasis, above. The dose of fibrolase used was 3.7 milligrams per kilogram, which was estimated to yield a final blood concentration of approximately 60 micrograms per milliliter in a 3.0-kilogram rabbit. This amount was chosen based on studies examining the inactivation of the enzyme in the presence of blood or plasma, presumably due to alpha<sub>2</sub>-macroglobulin (see pages 336 and 339).

40 [0017] In another *in vivo* study, the biological effect of recombinant fibrolase on clot lysis was examined in canines. Markland et al., Circulation, above. Four milligrams of this material per kilogram (of animal body weight) was infused over five minutes proximal to a pre-induced thrombus in the left carotid artery via a catheter device (see page 2450). Here again, it was noted that inactivation of fibrolase occurs in the general blood circulation presumably due to the presence of alpha<sub>2</sub>-macroglobulin (see page 2454, second column, last paragraph).

45 [0018] As these two studies show, the deactivating effects of alpha<sub>2</sub>-macroglobulin can be overcome by either administration or systemic dosages of fibrinolytic metalloproteinase that exceed the saturable level of innate alpha<sub>2</sub>-macroglobulin (the rabbit study) or by delivering the enzyme locally to the site of the clot (the dog study) and avoiding systemic administration. On the other hand, doses of the fibrinolytic metalloproteinase in excess of the saturable level of alpha<sub>2</sub>-macroglobulin, whether delivered systemically or locally, may exceed levels that are safe and well tolerated by the subject being treated. Notably, fibrinolytic metalloproteinases are capable of destroying not only fibrin, but they may also degrade other structural proteins and are therefore potentially toxic *in vivo* when present in large amounts that exceed the saturable level of alpha<sub>2</sub>-macroglobulin.

55 [0019] It is an object of the present invention to provide a safe and biologically effective way of using locally admin-

istered fibrinolytic metalloproteinases to lyse blood clots *in vivo*.

Summary of the Invention

5 [0020] Briefly stated, this invention relates to the treatment of a blood clot *in vivo*, in human subjects, by using a fibrinolytic metalloproteinase, comprising the local administration of a safe, biologically effective amount of the fibrinolytic metalloproteinase to the blood clot, such as by use of catheter delivery means.

10 [0021] According to the present invention, there is provided the use of a fibrinolytic metalloproteinase that complexes with alpha-two macroglobulin in a pharmaceutically acceptable solution for the manufacture of a medicament for the therapeutic treatment in a human subject of a blood clot by local administration to the blood clot by catheter delivery means, wherein the fibrinolytic metalloproteinase is for administration in an amount ranging between 0.025 and 1.7 milligrams of the fibrinolytic metalloproteinase per kilogram of body weight of the human subject being treated.

15 [0022] By "safe, biologically effective" amount is meant an amount sufficient to degrade fibrin and facilitate lysing of the clot (i.e., thrombus), while not exceeding levels significantly above the saturable level of  $\alpha_2$ -macroglobulin in the circulatory system of the patient being treated (i.e., levels that may cause damage to blood vessel walls). Typically, this amount will be in the range between 0.025 and 1.7 milligrams per kilogram of body weight for the human subject being treated, as determined from a study conducted with blood samples from human subjects that have been studied for *in vitro*  $\alpha_2$ -macroglobulin content and binding capacity. From the *in vitro* results of this study, it has been possible to define the saturable level *in vivo* of  $\alpha_2$ -macroglobulin for all practical purposes, thus enabling the delineation of a biologically effective amount that takes into account not only the minimum level of fibrinolytic metalloproteinase required for biological effectiveness, but also the maximum level for well tolerated administration. This study is described in detail further below among the Examples.

20 [0023] The use of this invention is applicable for *in vivo* treatment of stationary fibrin clots located in either native arterial or venous blood vessels, or in synthetic arterial or venous grafts, in humans.

25 [0024] The terms "locally" or "localized" as applied to the form of delivery of the fibrinolytic metalloproteinase herein refer to intra-arterial or intravenous administration either directly to the blood clot itself (i.e., intrathrombus) or in close proximity to the clot (either proximal or distal relative to blood flow) and near enough for the majority of the fibrinolytic metalloproteinase to be absorbed by the clot.

30 [0025] The term "catheter delivery means" is employed herein in the conventional sense of referring to a tubular medical device for insertion into canals, vessels, passageways or body cavities for the purpose of injecting or withdrawing fluids or to keep a passageway open. In general, such means will typically comprise an elongated flexible catheter body containing one or more interior passageways (or "lumens"); a proximal portion which allows material (i.e., clot lysing agent) to be introduced into the catheter body and to flow through the lumen; a distal portion optionally having a tapered end; and multiple exit ports at or near the end of the distal portion to permit material to exit the catheter in response to applied pressure.

35 [0026] The use of this invention is illustrated further below with respect to peripheral artery occlusion (PAD). PAO finds its origins in peripheral vascular disease due to atherosclerosis. The symptoms develop slowly over many years as atherosclerosis progresses, with a critical ischemic level being reached in about 15 to 20% of patients with lower extremity disease. Medical therapy is limited and predominantly aimed at prevention or risk reduction using medications such as lipid-lowering or antiplatelet agents, smoke cessation programs and physical exercise. Jackson and Clagett, *Chest*, Volume 114, pages 666S-682S (1998).

40 [0027] The clinical manifestations of peripheral vascular disease may include acute occurrences of limb-threatening ischemia or the presence of more chronic evidence of vascular disease (i.e., intermittent claudications). Outside of the aforementioned preventive measures, chronic PAO is typically not treated until the onset of severe lifestyle limitation or limb-threatening ischemia. Depending on the vessel segment affected and the extent of occlusion, available medical interventions include percutaneous transluminal angioplasty, surgical revascularization, and thrombolysis. Studies have shown that the intra-arterial infusion of clot lysing agents, particularly in the early stages of occlusion, can avoid the need for surgical intervention. As demonstrated in the Rochester trial, which compared thrombolysis with the plaminogen activator urokinase to surgery in the treatment of acute PAD (Ouriel et al., *Journal of Vascular Surgery*, 1994, Volume 19, pages 1021-1030), approximately 33 percent of patients in the thrombolysis arm of the study were successfully treated with medical intervention only, thereby avoiding a more invasive procedure. In contrast, 98 percent of patients in the operating arm were subjected to an endovascular or surgical procedure.

45 [0028] Other medical disorders involving occlusive blood clots can be effectively treated in a similar manner according to the invention, including, but not limited to, acute myocardial infarction, ischemic stroke, deep venous thrombosis and pulmonary embolism. The use of this invention can also be employed to dissolve clots which occur with chronically implanted medical devices such as indwelling catheters and hemodialysis access grafts.

Brief Description of the Figures**[0029]**

5 FIGURES 1A-1C. Figure 1A is a baseline angiogram of the carotid artery in an adult pig prior to balloon catheter induced-injury and the formation of an occlusive thrombus. The arrow indicates the position and the presence of contrast media in the left common carotid artery, indicating that blood flow in the artery is unobstructed (i.e., the blood vessel is "patent" or has "patency"). Figure 1B is an angiogram taken on day 4 in the same animal, prior to the administration of NAT in accordance with the method of this invention. The arrow indicates the position of the 10 left common carotid artery, however, contrast media does not flow in the artery due to the presence of an occlusive thrombus. Figure 1C is an angiogram at 2 hours following administration of 30 mg of NAT through a "PRO" catheter (see Figure 3 for an illustration of this device). The arrow indicates the presence of contrast media in the vessel, demonstrating that patency has been restored in the left carotid artery. Minimal residual thrombus is visible in the 15 lumen of the artery.

15 FIGURE 2 illustrates a type of catheter device designed for localized delivery of a thrombolytic agent in a blood vessel. The device, shown here in side cross-sectional view, contains "side holes" at the delivery end through which the infusate (thrombolytic agent) is emitted under applied fluid pressure. The diameters of the catheter tubes in this figure and the following figure relative to overall size are exaggerated to show the details better.

20 FIGURE 3 is a side cross-sectional view of an alternate type of catheter device for localized delivery of a thrombolytic agent in a blood vessel. This device contains thin slits, referred to as "pressure response outlets" (PRO), which have been cut into the catheter wall at regular intervals such that infusate escapes when the fluid pressure within the catheter reaches a critical point, causing the slit to open. The device can be used in conjunction with an 25 automated, piston-driven, pulsed infusion device (not shown, but exemplified further below) which is capable of delivering pulses of drug infusion.

Detailed Description of the Invention

30 [0030] The use of this invention is applicable for the therapeutic delivery of any fibrinolytic metalloproteinase that is capable of being complexed with  $\alpha_2$ -macroglobulin. Such fibrinolytic metalloproteinases, if naturally occurring, may be purified from their natural sources, e.g., fibrolase from snake venom. Alternatively, polypeptide fibrinolytic metalloproteinase agents the nucleic acid and amino acid sequences of which are known may be produced by utilizing conventional methods of recombinant expression and purification.

35 [0031] In general, recombinant methods employ a DNA molecule encoding the fibrinolytic metalloproteinase of interest which is inserted into an appropriate vector for expression in a suitable host cell. The Vector is selected to be functional in the particular host cell employed, i.e., is compatible with the host cell machinery, such that expression of the DNA can occur.

The vectors may also contain a 5' flanking sequence (also referred to as a "promoter") and other expression regulatory 40 elements operatively linked to the DNA to be expressed, as well as other known elements, such as an origin of replication element, a transcriptional termination element, a complete intron sequence containing a donor and acceptor splice site, a signal peptide sequence, a ribosome binding site element, a polyadenylation sequence, a polylinker region for inserting the encoding nucleic acid, and a selectable marker element. The vector may also optionally contain a "tag" sequence, i.e., an oligonucleotide sequence located at the 5' or 3' end of the polypeptide-coding sequence that encodes 45 polyHis or another small immunogenic sequence. This tag will be expressed along with protein of interest, and can serve as an affinity tag for purification of this polypeptide from the host cell. If desired, the tag can subsequently be removed from the purified polypeptide by various means, for example, with use of a selective peptidase.

50 [0032] In those cases where it is desirable for the polypeptide to be secreted from the host cell, a signal sequence may be used to direct the polypeptide out of the host cell where it is synthesized. Typically, the signal sequence is positioned in the coding region of nucleic acid sequence, or directly at the 5' end of the coding region. Many signal sequences have been identified, and any which are functional in the selected host cell may be used.

55 [0033] After the vector has been constructed and a nucleic acid has been inserted into the proper site of the vector, the completed vector may be inserted into a suitable host cell for amplification and/or polypeptide expression. Host cells may be prokaryotic (such as *E. coli*) or eukaryotic (such as a yeast cell, an insect cell, or a vertebrate cell).

[0034] Suitable host cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO) or 3T3 cells. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines are the monkey COS-1 and COS-7 cell lines, and the CV-1 cell line.

Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or may contain a dominantly acting selection gene. Still other suitable mammalian cell lines include but are not limited to, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines.

5 [0035] Also useful as host cells are bacterial cells, for example, various strains of *E. coli*, and various strains of yeast cells.

10 [0036] Insertion (also referred to as "transformation" or "transfection") of the vector into the selected host cell may be accomplished using such methods as calcium phosphate, electroporation, microinjection, lipofection or the DEAE-dextran method. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan.

15 [0037] The host cell, when cultured under appropriate conditions, can synthesize the fibrinolytic metalloproteinase of interest. The host cells may be cultured using standard media well known to the skilled artisan. The media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells are, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells are RPMI 1640, MEM, DMEM, all of which may be supplemented with serum and/or growth factors as required by the particular cell line being cultured.

20 [0038] Typically, an antibiotic or other compound useful for selective growth of the transformed cells only is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin.

25 [0039] The amount of protein produced in the host cell can be evaluated using standard methods known in the art, including Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, HPLC separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

30 [0040] If the protein is secreted from the host cells other than gram-negative bacteria, the majority will likely be found in the cell culture medium. If it is not secreted, it will be present in the cytoplasm. For intracellular protein, the host cells are typically first disrupted mechanically. For protein having a periplasmic location, either mechanical disruption or osmotic treatment can be used to release the periplasmic contents into a buffered solution, and the polypeptide is then isolated from this solution. Purification from solution can thereafter be accomplished using a variety of techniques.

35 [0041] If the protein has been synthesized so that it contains a tag such as hexahistidine or other small peptide at either its carboxyl or amino terminus, it may essentially be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag or for the polypeptide directly (i.e., a monoclonal antibody). Where the polypeptide has no tag and no antibodies are available, other well known procedures for purification can be used, for example, ion exchange chromatography, molecular sieve chromatography, reversed phase chromatography, HPLC, native gel electrophoresis in combination with gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific). In some cases, two or more of these techniques may be combined to achieve increased purity.

40 [0042] Novel Acting Thrombolytic (NAT) polypeptide utilized herein to illustrate the practice of this invention refers in general to the fibrinolytically active metalloproteinase of SEQ ID NO: 1. The NAT polypeptide is encoded by the cDNA molecule of SEQ ID NO: 2, although any DNA molecule of variant sequence encoding the same polypeptide may be used for expression and manufacture in accordance with specific methods which are referred to further below.

45 [0043] Fibrolase has been described in the scientific and patent literature; see references above. Typically, the form of fibrolase which is employed in the practice of this invention will be of SEQ ID NO: 3, which is encoded by the cDNA molecule of SEQ ID NO: 4 or variants thereof encoding the same amino acid sequence.

50 [0044] Preferably, a yeast expression system is employed for recombinant expression of NAT. Special mention is made of *Pichia* strains, for example, *Pichia pastoris*, as being the most advantageous and preferred for use. A detailed description of such a system may be found in United States Patent No. 4,855,231 (Stroman et al.), United States Patent No. 4,812,405 (Lair et al.), United States Patent No. 4,818,700 (Cregg et al.), United States Patent No. 4,885,242 (Cregg), and United States Patent No. 4,837,148 (Cregg). Expression of fibrolase in such a system will typically involve a DNA molecule of SEQ ID NO: 5, which encodes "prepro" sequence (nucleotides 1-783) in addition to the "mature" polypeptide (nucleotides 784-1392). The expression of NAT in such a system will typically involve a DNA molecule of SEQ ID NO: 6, which encodes "prepro" sequence (nucleotides 1-783) in addition to the "mature" polypeptide (nucleotides 784-1386).

55 [0045] The fibrinolytic metalloproteinase employed in accordance with this invention, whether it be NAT, fibrolase, or some other fibrinolytic metalloproteinase, is to be administered in the form of a pharmaceutically acceptable solution, alone or containing additional pharmaceutically acceptable ingredients. If desired, such solutions may comprise, in addition to the fibrinolytic metalloproteinase and a solvent (i.e., distilled water or physiological saline), standard ingredients such as stabilizers (to prevent protein aggregation or physical or chemical degradation in aqueous media),

bulking agents (to provide bulk), diluents, antibacterial agents, viscosity adjusting agents, anti-oxidants, and so forth, in conventional amounts. Known excipients which can be included in the formulation include polyols (including mannitol, sorbitol and glycerol); sugars (including glucose and sucrose); and amino acids (including alanine, glycine and glutamic acid). See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

5 [0046] Desirably, the pharmaceutical composition will be buffered (with a biocompatible buffering agent, for example, citric acid or citric acid salt) to a pH which is at or near neutral (7.0) prior to administration, and usually between about 6.5 and about 8.0 pH ( $\pm$  0.5).

10 [0047] If the metal ion of the fibrinolytic metalloproteinase is zinc, such as with fibrolase or NAT, it may be preferable to include a water soluble zinc salt (for example, zinc sulfate or zinc acetate) as a stabilizer. To further enhance the long-term stability and shelf life of the composition, it may also be advantageous to freeze the solution or to convert it to a lyophilized (freeze-dried) product which is thawed or reconstituted prior to use, as the case may be.

15 [0048] By way of illustration, a freezable liquid medicinal composition which may be employed in the method of this invention comprises fibrolase or NAT, a water soluble zinc salt, a citric acid buffer, optionally an additional stabilizer selected from the group consisting of water soluble calcium salts, and optionally a bulking agent (for example, mannitol).

20 [0049] A surfactant, such as Tween 80 (BASF, Gurnee, Illinois), may also be added to increase freeze-thaw stability. Tris buffer (Sigma, St. Louis, Missouri) or another buffer with a buffer capacity above pH 7.0 may be added to stabilize the pH at or above pH 7.4. Most of these ingredients will be present in minor amounts ranging from 0.001 to 2.0 millimolar (mM) or less than ten percent (w/v). The buffering agent will be added in an amount sufficient to achieve the desired pH, and this amount may vary depending on the specific formulation.

25 [0049] By way of further illustration, a lyophilizable or lyophilized pharmaceutical composition which can be used according to this invention comprises fibrolase or NAT, a zinc stabilizer (e.g., water soluble zinc salt such as the above), and a citric acid buffer, with or without other excipients (e.g., bulking agent such as mannitol, glycine, or the like). The lyophilized composition may also contain a disaccharide sugar, such as sucrose or trehalose, as a lyoprotectant. A surfactant, such as Tween 80, may be added to protect against lyophilization stresses on the fibrinolytic metalloproteinase (e.g., fibrolase or NAT). The pH will ideally be maintained at pH  $8.0 \pm 0.5$ , using a suitable buffer with a  $pK_a$  in this range (for example, Tris).

Amounts of ingredients will be in accordance with the above.

30 [0050] As mentioned, the use of this invention is employed to locally administer biologically effective amounts of a fibrinolytic metalloproteinase that are in the range between 0.025 and 1.7 mg/kg. Preferably, this amount will in the range from about 0.1 to about 0.5 mg/kg. Solution strengths will be formulated accordingly, with dilution be effected as needed upon administration.

35 [0051] In the typical case, the use of this invention is carried out in conjunction with a catheter-directed thrombolysis procedure. Such procedures involve the use of a pre-sterilized catheter-type drug delivery device, the side walls of which may be made of a thin, semi-rigid or flexible biocompatible material (for example, a polyolefin, fluoropolymer, or other inert polymer). In general, suitable catheters contain at least one interior cavity (or lumen) running the length of the device. The material from which the catheter is constructed is flexible enough to be moved through the interior of the vasculature without causing injury to the blood vessel walls, yet sufficiently rigid to extend over a distance to the site of treatment while the interior cavity of the device remains fully distended. Typically, such catheter devices will range from 2 to 20 on the French scale for catheter diameters (1/3 millimeter equals 1 French) and from two to six feet or more in length.

40 [0052] Exemplary catheter devices for the intravascular delivery of thrombolytic medication in accordance with this invention are illustrated in Figures 2 and 3, the practical applications of which are described in detail in the examples below. However, any conventional catheter delivery device which is suitable for this method may be utilized, including but not limited to the specific devices referred to herein.

45 [0053] An effective dose of fibrinolytic metalloproteinase can be delivered through the catheter to the local site of treatment by pulsatile infusion, continuous infusion, bolus administration, or a combination of all three. The solution strength (i.e., concentration) of fibrinolytic metalloproteinase in the treatment solution is an important parameter. More specifically, a range between the minimum dilution of the fibrinolytic metalloproteinase for effectiveness at the lower end (which is especially important for bolus administration) and the maximum solubility of the fibrinolytic metalloproteinase at the higher end should be selected. In general, solution strengths in the range from about 0.1 to about 80 mg/mL are employed. The volume of the bolus (or total volume of multiple boluses in the case of a "pulsed" delivery) is then selected accordingly to deliver an effective amount of fibrinolytic metalloproteinase within the ranges prescribed above.

55 Description of Specific Embodiments

[0054] The invention is further illustrated in the following examples, which are meant to be illustrative only and not to limit the invention to the described embodiments. In these examples, and throughout the description of this invention,

"kg" indicates kilograms of body weight per test subject, "mg" indicates milligrams, "mL" indicates milliliters, and "min" indicates minutes. The fibrinolytic metalloproteinase illustrated, namely Novel Acting Thrombolytic (NAT), was recombinant-derived and made in accordance with methods referred to above.

5 EXAMPLE 1

Thrombolysis in Subacute Thrombosis of the Adult Pig Common Carotid Artery

[0055] NAT was been studied in a model of subacute thrombosis of the carotid artery in adult pigs, averaging 75 kg in body weight, at a contract laboratory (Charles River Laboratories, Southbridge, Massachusetts). The intent of this study was to establish the fibrinolytic activity of NAT in a thrombosis model which is relevant to peripheral artery occlusion in humans.

[0056] In this animal model, the carotid artery was thrombosed along its entire length (approximately 20 centimeters from origin at the aorta to the carotid bifurcation) by a combination of balloon injury, thrombin and stasis. The size of the thrombus approaches the size of thrombus encountered clinically in humans with peripheral arterial occlusion. After successful thrombosis, the animal was allowed to recover for a period of four days. A four-day period was selected to allow extensive cross-linking of fibrin, remodeling of thrombus, and infiltration of cells. Notably, both the size and age of the thrombus in this model are reasonable representations of the size and duration of ischemic symptoms reported in the most recently published TOPAS trial of thrombolysis with plasminogen activators in peripheral arterial occlusion in humans. For reference, see Ouriel et al., New England Journal of Medicine, Volume 338, pages 1105-1111 (1998).

[0057] Briefly, the common carotid artery can be thrombosed along its entire length by fluoroscopically directed balloon injury. The balloons that are used are oversized and non-compliant. The balloons are inflated at pressures of up to twelve atmospheres, which causes a crushing injury to the intimal layer of the vessel. While the balloon is inflated, it is moved back and forth in order to strip away the vascular endothelium.

[0058] The ballooning procedure is very injurious and creates a highly thrombogenic vessel surface and is repeated throughout the entire length of the common carotid artery. After thoroughly injuring the entire artery, the balloon is withdrawn to a proximal position near the aorta and inflated to occlude flow of blood through the vessel. While occluded, fifty Units of bovine thrombin is injected through the distal port of the balloon catheter in order to stimulate coagulation. The balloon remains inflated for a period of thirty minutes, which results in thrombotic occlusion of the vessel. After thirty minutes, the balloon is deflated and an angiogram is performed to confirm that the vessel has become occluded. With these procedures, occlusion of the vessel was achieved in greater than ninety percent of cases.

[0059] Once thrombosed, the balloon catheter, guide catheter and access sheath are removed and the animal is allowed to recover over a period of four days. On the fourth day, the animals are re-anesthetized, the occlusion is reconfirmed, and a multiple side hole drug delivery catheter (see Figures 2 and 3) is advanced under fluoroscopic guidance and positioned such that the side holes are located within the thrombus. Thrombolysis with NAT was angiographically observed using fixed NAT dosages which ranged from 10 to 30 mg (or approximately 0.1 to 0.4 mg/kg on a weight adjusted basis), as shown in Figures 1A-1C.

[0060] As the image in Figure 1B illustrates, NAT is effective in restoring antegrade flow as assessed by angiography. To be more quantitative, flow in the target vessel is qualitatively scored according to a 4-point scale (ranging from 0 to 40) where:

- 0 = no flow
- 1 = flow estimated to be less than 30% of the contralateral (non-thrombosed) carotid
- 2 = flow estimated to be 30-80% of the contralateral carotid
- 3 = flow which is indistinguishable from the contralateral carotid

[0061] The image shown in Figure 1B was scored as flow grade equal to 3, a frequent result in thrombosed vessels treated with a fixed 30 mg dosage of NAT (approximately 0.4 mg/kg in a 75 kg pig). Tables 1-3 in the following examples below illustrate the treatment regimen and mean flow scores derived from serial angiograms. In all of the studies, respiration, body temperature, heart rate and arterial blood pressures were continually monitored and remained within physiologic ranges with no changes observed upon administration of NAT.

EXAMPLE 2

55 Selection of PRO Catheters and Pulse-Spray Delivery

[0062] In the clinical management of peripheral arterial occlusion, thrombolytic agents are delivered through catheters which are positioned near or embedded into the thrombus. As shown in Figures 2 and 3, there are two types of

catheters.

[0063] One variety, the "side hole" catheter (Fig. 2), has tiny round side holes (2) cut into the catheter (4) near closed distal end 6, and an entry port 8 (for the solution of fibrinolytic metalloproteinase) in mating ring 10 affixed at proximal end 12. Catheter 4 is constructed of a flexible, elongated, biocompatible polymer tubing material which is hollow and thin-walled and has a uniform diameter of 2 to 20 French, and preferably 3 to 5 French. The catheter contains two radiopaque markers 14 on the exterior surface near distal end 6 which demarcate the portion of the catheter containing side holes 2. In practice, the catheter is inserted into a surgical opening in the occluded artery or vein and, while being observed via fluoroscopy in accordance with standard approved procedures, is moved carefully through the blood vessel such that distal end 6 is positioned into or near the thrombus. Markers 14, which show up clearly on a fluoroscope image, can serve as a guide for positioning that portion of the catheter such that infusate emerging from side holes 2 will contact the thrombus directly. A pharmaceutical solution of the fibrinolytic metalloproteinase is then injected under gentle pressure from syringe-like reservoir 16 into entry port 8 and is impelled toward distal end 6, emerging through holes 2 into the thrombus, causing degradation of the fibrinous material.

[0064] When infusions of a fibrinolytic metalloproteinase are performed using this type of catheter, most of the fibrinolytic agent-containing solution tends to escape through the proximal side holes (i.e., those nearest to drug entry port 8), which has a negative impact in the uniformity of drug delivery at the site of treatment. There is also a possibility of backflow of blood into the catheter through side ports 2 under negative pressure.

[0065] Another variety of catheter, also composed of a hollow, thin-walled, biocompatible polymer material, shown in Figure 3, has extremely thin slits 2 that are laser cut into flexible catheter 4 at regular intervals near closed distal end 6. The slits, which are referred to as pressure response outlets ("PRO"), are tight enough that infusate will not escape unless the fluid pressure within the catheter reaches a critical point and causes the slits to distend simultaneously and thus open temporarily. The catheter can also contain exterior radiopaque markers 8 to assist in the positioning of the device at the site of the thrombus.

[0066] Ideally, such "PRO" infusion catheters are used in conjunction with an automated, piston-driven, pulsed infusion device (not shown) that is capable of delivering low volume regulated pulses of drug infusion into entry port 10 in mating ring 12 affixed at proximal end 14 of catheter 4. When a pulse is delivered, the pressure within the catheter rises momentarily. In response, the pressure response outlets (slits 2) open momentarily and allow the infusate (e.g., pharmaceutical solution of fibrinolytic metalloproteinase) to escape. The theoretic advantage of pulsed delivery of infusate and a PRO-type catheter is that infusate is delivered uniformly through the slits along the entire length of the catheter, whereas infusate delivered through the "side hole" catheter (Figure 2) follows a path of least resistance and flows out the proximal side holes in a non-uniform manner as mentioned.

[0067] A pig model of four-day old carotid thrombosis was utilized to assess performance of the above mentioned two catheter types, using fixed dosages of 30 mg of NAT (approximately 0.4 mg/kg in a 75 kg pig). The results are summarized in Table 1.

TABLE 1

Comparison of Angiographic Flow Scores Obtained with NAT Using Side Hole and PRO Infusion Catheters								
40	DRUG	DOSE	CATH	DELIV TIME (delivery)	ANGIOGRAPHIC FLOW SCORE			
					0	30m	1hr	2hr
NAT n=5	30 mg	CM	60 min (infusion)	0.0 ± 0.0	1.2 ± 0.4	1.6 ± 0.5	1.8 ± 0.4	2.0 ± 0.7
NAT n=4	30 mg	PS	60 min (0.1mL pulse)	0.0 ± 0.0	1.5 ± 0.6	1.5 ± 0.6	2.3 ± 0.5	2.5 ± 0.6

CM: Cragg-McNamara™ valved infusion "side hole" type catheter (Micro Therapeutics, Inc., San Clemente, California). PS: "pulse-spray" delivery as defined by use of pressure response outlet (PRO) catheter (Uni\*Fuse Catheter™, AngioDynamics, Inc., Queensbury, New York) used in conjunction with automated, pulsed infusion device (PULSE\*SPRAY INJECTOR Model PSI-1, AngioDynamics, Inc., Queensbury, New York).

[0068] As shown in Table 1, angiographic flow scores in the group treated with the pulse-spray modality showed slightly higher initial flow scores at the thirty-minute angiogram which appeared to persist to the four-hour timepoint. Although statistical differences were not obtained, the angiographic results have generally been judged to be superior. Therefore, a PRO-type catheter in conjunction with pulse-spray delivery is the preferred mode of delivery for a fibrinolytic

metalloproteinase in accordance with this invention.

EXAMPLE 3

5 Assessment of Drug Delivery Time

[0069] Acute peripheral arterial occlusion is typically treated with plasminogen activators, such as urokinase, delivered as an infusion which is often twenty-four hours in duration, and occasionally as long as forty-eight hours. The lengthy infusion is presumed to maintain a low level of plasmin generation over a prolonged period of time in order to effectively dissolve the occlusive thrombus. As both NAT and fibrolase are fibrinolytic metalloproteinases, such prolonged infusions may not be necessary. To assess whether the delivery rate affects angiographic clot lysis, a fixed 30 mg dose of NAT (roughly 0.4 mg/kg in a 75 kg pig) was delivered using PRO catheters and the pulse spray device. Using 0.1 mL pulse volumes, a 5 mg/mL NAT solution was delivered over six minutes (ten pulses per minute) or over sixty minutes (one pulse per minute). The results are shown in Table 2.

15 TABLE 2

Comparison of Drug Delivery Times for NAT Delivered by PRO Catheter and Pulse-Spray Injector								
DRUG	DOSE	CATH	DELIV TIME (pulse volume)	ANGIOGRAPHIC FLOW SCORE				
				0	30m	1hr	2hr	4hr
NAT n=3	30 mg	PS	6 min (0.1mL)	0.0 ± 0.0	2.7 ± 0.6	2.7 ± 0.6	2.7 ± 0.6	2.7 ± 0.6
NAT n=3	30 mg	PS	60 min (0.1mL)	0.0 ± 0.0	0.0 ± 0.0	1.0 ± 1.0	1.3 ± 1.2	1.7 ± 0.6

[0070] As shown in Table 2, the delivery of 30 mg NAT over six minutes resulted in a mean flow score of 2.7 in the three animals at the thirty-minute angiogram, which persisted out to the four-hour timepoint. In contrast, the delivery of 30 mg of NAT by pulsed infusion over sixty minutes was far less impressive. Although these data have not been statistically compared, the results appear to favor delivery of NAT as a more rapid pulse regimen.

30 EXAMPLE 4

35 Optimization of Pulse Volume

[0071] The pulse-spray infusion device is programmable for delivering pulse volumes of 0.1 to 0.5 mL per pulse. To determine if the pulse volume had any effect on the angiographic outcomes in the pig model, pulse volumes of 0.2 mL were compared to pulse volumes of 0.4 mL. NAT was delivered at a fixed dose of 10 mg (equivalent to 0.15 mg/kg in a 75 kg pig). The results are shown in Table 3.

40 TABLE 3

Comparison of Angiographic Results Using NAT Delivered in Pulse Volumes of 0.2 mL or 0.4 mL								
DRUG	DOSE	CATH	DELIV TIME (pulse volume)	ANGIOGRAPHIC FLOW SCORE				
				0	30m	1hr	2hr	4hr
NAT n=7	10 mg 2.5 mg/mL	PS	5 min (0.2mL q15sec)	0.0 ± 0.0	1.0 ± 0.6	1.1 ± 0.7	1.6 ± 1.0	1.4 ± 1.1
NAT n=6	10 mg 2.5 mg/mL	PS	5 min (0.4mL q30sec)	0.0 ± 0.0	1.2 ± 0.4	1.0 ± 0.6	0.8 ± 0.8	1.0 ± 0.6

[0072] As shown in Table 3, at thirty minutes the mean angiographic score was slightly higher in the 0.4 mL pulse volume group. However, at the four-hour time point, the group mean was slightly higher in the 0.2 mL pulse volume. As such, no conclusion can be drawn from these studies with regard to one pulse volume being superior to another.

[0073] The results in preceding text and tables suggest that virtually all of these NAT treatment regimens are effective

in treating peripheral artery occlusions with the method of delivery of this invention, and that these results are at least comparable to treatment with plasminogen activators, such as urokinase, which is the current treatment of choice with thrombolytic agents.

5 [0074] The results demonstrate that the PRO catheter with pulse-spray delivery appears to provide superior angiographic results. Given the body weight of animals in these studies (70-100 kg), the fixed dosage of 30 mg is roughly equivalent to 0.3-0.4 mg/kg on a weight-adjusted basis.

10 [0075] Lowering the fixed dosage NAT to 10 mg resulted in a reduction of group mean angiographic scores at four hours and in some animals, patency was not achieved. This indicates that a dose of 10 mg of NAT appears to be a threshold dose for biologic activity in this model. Given the body weight of animals in these studies (70-100 kg), the fixed dosage of 10 mg is roughly equivalent to 0.1-0.15 mg/kg on a weight-adjusted basis. Varying the pulse volume from 0.2 mL to 0.4 mL did not appear to profoundly impact the angiographic patency scores.

#### EXAMPLE 5

##### 15 Establishment of Safe, Well Tolerated, Biologically Effective Dose Range in Humans

20 [0076] No satisfactory literature exists on the serum concentration or biochemical activity of  $\alpha_2$ -macroglobulin in elderly patients with peripheral vascular disease (PWD). As  $\alpha_2$ -macroglobulin concentrations are a key determinant of the safety and likely to be related the tolerability of fibrinolytic metalloproteinases *in vivo*, a cross-sectional epidemiological study was conducted in patients with PVD to evaluate serum  $\alpha_2$ -macroglobulin concentration and the fibrinolytic metalloproteinase binding capacity (using NAT as the test agent).

25 [0077] Two hundred and sixteen patients were enrolled at two centers (Cleveland Clinic Foundation, Cleveland, OH, and Rochester General Hospital, Rochester, NY). Demographic information and other patient characteristics were collected and serum was obtained for measuring  $\alpha_2$ -macroglobulin, the NAT binding capacity (by titration of individual patient serum samples using an HPLC assay that detects unbound NAT) and other serum chemistry parameters. The primary endpoint was the determination of the relationship between the serum concentration of  $\alpha_2$ -macroglobulin and the amount of NAT (in micrograms per milliliter of serum) that could be neutralized *in vitro* (NAT binding capacity).

30 [0078] A comparison of patient characteristics in this study with those of the two largest published studies of thrombolysis in PAO (i.e., the STILE and TOPAS studies) indicated that the patient population in this study was representative of previous studies of thrombolysis in PAO; For further details on the previous studies, see Annals of Surgery, Volume 220, pages 251-266 (1994) and Ouriel et al., New England Journal of Medicine, Volume 338, pages 1105-1111 (1998), respectively.

35 [0079] The estimated maximum dose (EMD) for NAT was calculated for each patient using the NAT binding capacity and an estimate of each patient's plasma volume. The study results predict that the average patient could receive a dosage of 1.7 mg/kg (delivered either locally or systemically) without exceeding the capacity of  $\alpha_2$ -macroglobulin to bind and neutralize NAT. The results from the study are summarized in Table 4, below.

40

45

50

55

TABLE 4

5      Histogram of Estimated Maximum Dose of NAT in  
Patients with Peripheral Vascular Occlusion

10


15

20

25

30

35



[0080] The estimated maximum dose of NAT was calculated for each of the 216 subjects in the study. The results for the study are depicted as a histogram, above, where a bell-shaped distribution can be observed by visual inspection. The average patient in this study is predicted to be capable of tolerating 1.7 mg/kg of NAT (the peak of the bell-shaped distribution). Dosages administered in animal studies are shown for reference (right hand side) and can be seen to be in excess of the estimated maximum dose of NAT for 99% of the study population.

[0081] Thus, the prescribed range of 0.025 to 1.7 mg/kg for the invention represents a rational estimate of the dose patients can safely receive (based on plasma volume and NAT binding capacity for  $\alpha_2$ -macroglobulin) without the appearance of free NAT in the circulation.

[0082] In conclusion, the results from the exemplified pharmacology studies, Examples 1-4, above, indicate the biological effectiveness of a fibrinolytic metalloproteinase as a clot lysing agent in an animal model of thrombosis where the thrombus is comparable in size and age to that frequently encountered in peripheral arterial occlusion in humans. The dosages identified in the animal models were obtained without regard for or assessment of the potential toxicities in the animal. The effective dosages in rabbits and dogs (3.7 and 4.0 mg/kg, respectively) as described by Ahmed et al. and Markland et al. (above) might enable a veterinary use for fibrinolytic metalloproteinases. However, when considered in the presence of human data, the administration of doses of 3.7 and 4.0 mg/kg would have overdosed 99 percent of the study population. Therefore, the published animal studies do not enable the therapeutic use of fibrinolytic metalloproteinases in humans in a manner that is safe as well as biologically effective. The data presented in Example 5, on the other hand, do enable such use in humans.

## SEQUENCE LISTING

[0083]

5           <110> Amgen Inc.

10           <120> METHOD FOR LOCALIZED ADMINISTRATION OF FIBRINOLYTIC METALLOPROTEINASES

15           <130> A-627

20           <140> N/A

25           <141> 1999-12-17

30           <160> 6

35           <170> PatentIn Ver. 2.1

40           <210> 1

45           <211> 201

50           <212> PRT

55           <213> Artificial Sequence

60           <220>

65           <223> Description of Artificial Sequence: NAT (analog of fibrolase of Agkistrodon Contortrix)

70           <400> 1

75           Ser Phe Pro Gln Arg Tyr Val Gln Leu Val Ile Val Ala Asp His Arg  
80           1                   5                   10                   15

85           Met Asn Thr Lys Tyr Asn Gly Asp Ser Asp Lys Ile Arg Gln Trp Val  
90           20                   25                   30

95           His Gln Ile Val Asn Thr Ile Asn Glu Ile Tyr Arg Pro Leu Asn Ile  
100           35                   40                   45

105           Gln Phe Thr Leu Val Gly Leu Glu Ile Trp Ser Asn Gln Asp Leu Ile  
110           50                   55                   60

115           Thr Val Thr Ser Val Ser His Asp Thr Leu Ala Ser Phe Gly Asn Trp  
120           65                   70                   75                   80

125           Arg Glu Thr Asp Leu Leu Arg Arg Gln Arg His Asp Asn Ala Gln Leu  
130           85                   90                   95

135           Leu Thr Ala Ile Asp Phe Asp Gly Asp Thr Val Gly Leu Ala Tyr Val  
140           100                   105                   110

145           Gly Gly Met Cys Gln Leu Lys His Ser Thr Gly Val Ile Gln Asp His  
150           115                   120                   125

155           Ser Ala Ile Asn Leu Leu Val Ala Leu Thr Met Ala His Glu Leu Gly  
160           130                   135                   140

155           His Asn Leu Gly Met Asn His Asp Gly Asn Gln Cys His Cys Gly Ala  
160           145                   150                   155                   160

Asn Ser Cys Val Met Ala Ala Met Leu Ser Asp Gln Pro Ser Lys Leu  
 165 170 175

5 Phe Ser Asp Cys Ser Lys Lys Asp Tyr Gln Thr Phe Leu Thr Val Asn  
 180 185 190

Asn Pro Gln Cys Ile Leu Asn Lys Pro  
 195 200

10

&lt;210&gt; 2

&lt;211&gt; 603

&lt;212&gt; DNA

15 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Encodes NAT (analog of fibrolase)

20

&lt;400&gt; 2

tctttccac aaagataacgt acagctggtt atcggtgctg accaccgtat gaacactaaa 60  
 tacaacggtg actctgacaa aatccgtcaa tgggtgcacc aaatcgtaaa caccattaaac  
 120  
 gaaatctaca gaccactgaa catccaattc actttggttg gtttggaaat ctgggtccaaac  
 180  
 caagatttga tcaccgttac ttctgtatcc cacgacactc tggcatcett cggtaactgg  
 240  
 300  
 cgtgaaacccg acctgctgctg tcgccaacgt catgataacg ctcaactgct gaccgctatc  
 360  
 gacttcgacg gtgatactgt tggctggct tacgttggtg gcatgtgtca actgaaaacat  
 420  
 tctactggtg ttatccagga ccactccgct attaacctgc tggttgtct gaccatggca  
 480  
 540  
 cacaactgg gtcataacct gggatgaac cacgatggca accagtgtca ctgcggtgca  
 500  
 aactccctgtg ttatggctgc tatgctgtcc gatcaaccat ccaaactgtt ctccgactgc  
 560  
 tctaaagaaag actaccagac cttcctgacc gttacaacc cgcagtgtat cctgaacaaa  
 600  
 ccg  
 603

45

&lt;210&gt; 3

&lt;211&gt; 203

&lt;212&gt; PRT

&lt;213&gt; Agkistrodon contortrix

50

&lt;220&gt;

&lt;223&gt; Native fibrolase of Agkistrodon Contortrix

&lt;400&gt; 3

55

Gln Gln Arg Phe Pro Gln Arg Tyr Val Gln Leu Val Ile Val Ala Asp  
 1 5 10 15

5	His	Arg	Met	Asn	Thr	Lys	Tyr	Asn	Gly	Asp	Ser	Asp	Lys	Ile	Arg	Gln
							20							25		30
	Trp	Val	His	Gln	Ile	Val	Asn	Thr	Ile	Asn	Glu	Ile	Tyr	Arg	Pro	Leu
							35				40			45		
10	Asn	Ile	Gln	Phe	Thr	Leu	Val	Gly	Leu	Glu	Ile	Trp	Ser	Asn	Gln	Asp
							50			55			60			
15	Leu	Ile	Thr	Val	Thr	Ser	Val	Ser	His	Asp	Thr	Leu	Ala	Ser	Phe	Gly
							65			70			75			80
20	Asn	Trp	Arg	Glu	Thr	Asp	Leu	Leu	Arg	Arg	Gln	Arg	His	Asp	Asn	Ala
							85			90			95			
25	Gln	Leu	Leu	Thr	Ala	Ile	Asp	Phe	Asp	Gly	Asp	Thr	Val	Gly	Leu	Ala
							100			105			110			
30	Tyr	Val	Gly	Gly	Met	Cys	Gln	Leu	Lys	His	Ser	Thr	Gly	Val	Ile	Gln
							115			120			125			
35	Asp	His	Ser	Ala	Ile	Asn	Leu	Leu	Val	Ala	Leu	Thr	Met	Ala	His	Glu
							130			135			140			
40	Leu	Gly	His	Asn	Leu	Gly	Met	Asn	His	Asp	Gly	Asn	Gln	Cys	His	Cys
							145			150			155			160
45	Gly	Ala	Asn	Ser	Cys	Val	Met	Ala	Ala	Met	Leu	Ser	Asp	Gln	Pro	Ser
							165			170			175			
50	Lys	Leu	Phe	Ser	Asp	Cys	Ser	Lys	Lys	Asp	Tyr	Gln	Thr	Phe	Leu	Thr
							180			185			190			
55	Val	Asn	Asn	Pro	Gln	Cys	Ile	Leu	Asn	Lys	Pro					
							195			200						

40 <210> 4  
<211> 609  
<212> DNA  
<213> *Aqkistrodon contortrix*

45 <220>  
<223> Encodes native fibrolase of Agkistrodon Contortrix  
<400> 4

50 caacaagat tcccacaaag atacgtacag ctggttatcg ttgctgacca ccgtatgaac 60  
actaaataca acggtgactc tgacaaaatc cgtcaatggg tgcacccaaat cgtcaacacc  
120  
attnacgaaa tctacagacc actgaacatc caattcaactt tggttggttt gggaaatctgg  
180  
tccaaaccaag atttgatcac cgttacttct gtatcccacg acactctggc atccttcggt  
240  
55 aactggcgtg aaacccgaccc gctgcgtcgc caacgtcatg ataacgctca actgctgacc  
300

5 gctatcgact tcgacggta tactgttggt ctggcttacg ttgggtggcat gtgtcaactg  
360  
aaacattcta ctgggtttat ccaggaccac tccgctatta acctgctggt tgctctgacc  
420  
atggcacacg aactgggtca taacctgggt atgaaccacg atggcaacca gtgtcaactgc  
480  
540 ggtgcaaact cctgtgttat ggctgctatg ctgtccgatc aaccatccaa actgttotcc  
600  
609 aacaaaccg

15 <210> 5  
<211> 1392  
<212> DNA  
<213> Agkistrodon contortrix

20 <220>  
<223> Native profibrolase of Agkistrodon Contortrix

25 <400> 5

30

35

40

45

50

55

atgagatttc cttcaatttt tactgctgtt ttattcgacatccctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgcgtatcggt  
 120  
 tactcagatt tagaagggaa tttcgatgtt gctgtttgc cattttccaa cagcacaaat  
 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta  
 240  
 tctctcgaga aaagagagggc tgaagcttct tctattatct tggaaatctgg taacgttaac  
 300  
 10 gattacgaag ttgttatcc aagaaaggtc actccagttc ctaggggtgc tggtaaccca  
 360  
 aagtacgaag atgccatgca atacgaattc aaggttaaca gtgaaccagt tgcgttgcac  
 420  
 ttggaaaaaa acaaagggtt gttctctgaa gattactctg aaactcatta ctccccagat  
 480  
 ggttagagaaa ttactactta cccattgggt gaagatcaact gttactacca tggtagaaatc  
 540  
 gaaaacgatg ctgactccac tgctctatc tctgcttgta acggttgaa gggtcatttc  
 600  
 20 aagttgcaag gtgaaatgta cttgattgaa ccattggaaat tgcgttgcac tgaagcccat  
 660  
 gctgttaca agtacgaaaaa cgtcgaaaag gaagatgaag cccaaagat gttgtgtt  
 720  
 accaaaaact gggaaatcata tgaaccaatc aagaaggcttccaaataaa cttgactaag  
 780  
 agacaacaaa gattcccaca aagatacgta cagctggta tgcgttgcac ccaccgtatg  
 840  
 aacactaaat acaacggtga ctctgacaaa atccgtcaat gggtgcacca aatcgtaac  
 900  
 30 accattaacg aaatctacag accactgaac atccaaattca ctttggttgg tttggaaatc  
 960  
 tggtccaaacc aagatttgat caccgttact tctgtatccc acgacactct ggcatttc  
 1020

35  
 ggttaactggc gtgaaaccga cctgctgcgt cgccaaacgac atgataacgc tcaactgctg  
 1080  
 accgctatcg acttcgacgg tgatactgtt ggtctggctt acgttgggtgg catgtgtcaa  
 40 1140  
 ctgaaaacatt ctactgggtt tatccaggac cactccgcta ttaacctgct gttgtctg  
 1200  
 accatggcac acgaactggg tcataacctg ggtatgaacc acgatggcaa ccagtgtcac  
 1260  
 45 tgcggtgcaa actccctgtt tatggctgct atgctgtccg atcaaccatc caaactgttc  
 1320  
 tccgactgct ctaagaaaga ctaccagacc ttccctgaccg ttaacaaccc gcagtgtatc  
 1380  
 ctgaacaaac cg  
 50 1392

<210> 6  
 <211> 1386  
 55 <212> DNA  
 <213> Artificial Sequence  
 <220>

&lt;223&gt; Description of Artificial Sequence: proNAT (analog of profilbrolase of Agkistrodon Contortrix

&lt;400&gt; 6

5           atgagatttc cttcaatttt tactgctgtt ttattcgcag catcctccgc attagctgct 60  
 ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt  
 120  
 tactcagatt tagaagggga tttegatgtt gctgtttgc catttccaa cagcacaaat  
 180  
 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta  
 240  
 tctctcgaga aaagagaggc tgaagcttct tctattatct tggaatctgg taacgttaac  
 300  
 gattacgaag ttgttatcc aagaaaggtc actccagttc cttagggtgc tgttcaacca  
 360  
 360  
 aagtacgaag atgccatgca atacgaattc aaggtaaca gtgaaccagt tgtcttgac  
 420  
 ttggaaaaaaaa acaaagggtt gttctctgaa gattactctg aaactcatta ctccccagat  
 480  
 ggttagagaaa ttactactta cccattgggt gaagatcact gttactacca tggtagaaatc  
 540  
 540  
 gaaaacgatg ctgactccac tgcttctatc tctgcttgta acggttgaa gggtcatttc  
 600  
 aagtgcag gtgaaatgta cttgattgaa ccattggaat tgtccgactc tgaagcccat  
 660  
 660  
 gctgtctaca agtacgaaaaa cgtcgaaaag gaagatgaaag ccccaaagat gtgtggtgtt  
 720  
 accccaaact gggaaatcata tgaaccaatc aagaaggcct tccaaattaaa ctgactaag  
 780  
 780  
 agatcttcc cacaagata cgtacagctg gttatcgttg ctgaccacccg tatgaacact  
 840  
 840  
 aaatacaacg gtgactctga caaaatccgt caatgggtgc accaaatcgt caacaccatt  
 900

35

40           aacgaaatct acagaccact gaacatccaa ttcaactttgg ttggtttggaa aatctggtcc  
 960  
 aaccaagatt tgatcaccgt tacttctgta tcccacgaca ctctggcatc cttcggttaac  
 1020  
 tggcgtgaaa ccgacctgct gcgtcgccaa cgtcatgata acgctcaact gctgaccgct  
 1080  
 1080  
 atcgacttcg acggtgatac tgggtgtctg gcttacgttg gtggcatgtg tcaactgaaa  
 1140  
 1140  
 cattctactg gtgttatcca ggaccactcc gctattaacc tgctgggtgc tctgaccatg  
 1200  
 1200  
 gcacacgaac tgggtcataa cctgggtatg aaccacgatg gcaaccagtg tcaactgcggt  
 1260  
 1260  
 gcaaactcct gtgttatggc tgctatgctg tccgatcaac catccaaact gttctccgac  
 1320  
 1320  
 tgctctaaga aagactacca gaccttcctg accgttaaca acccgcagtg tatcctgaac  
 1380  
 1380  
 aaaccg  
 1386

**Claims**

1. Use of a fibrinolytic metalloproteinase that complexes with alpha-two macroglobulin in a pharmaceutically acceptable solution for the manufacture of a medicament for the therapeutic treatment in a human subject of a blood clot by local administration to the blood clot by catheter delivery means, wherein the fibrinolytic metalloproteinase is for administration in an amount ranging between 0.025 and 1.7 milligrams of the fibrinolytic metalloproteinase per kilogram of body weight of the human subject to be treated.

5 2. A use according to Claim 1, wherein the amount of the fibrinolytic metalloproteinase is in the range from about 0.1 to about 0.5 milligram per kilogram of body weight.

10 3. A use according to Claim 1 or 2, wherein the fibrinolytic metalloproteinase is for delivery via intrathrombus administration.

15 4. A use according to any one of Claims 1 to 3, wherein the fibrinolytic metalloproteinase is for administration in the close proximity of the blood clot.

5 5. A use according to any one of Claims 1 to 4, wherein the blood clot is located in an artery.

20 6. A use according to Claim 5, wherein the medicament is for treatment of peripheral artery occlusion.

7. A use according to any one of Claims 1 to 4, wherein the blood clot is located in a vein.

25 8. A use according to any one of Claims 1 to 4, wherein the human subject has peripheral vascular disease.

9. A use according to any one of Claims 1 to 4, wherein the peripheral vascular disease is due to atherosclerosis.

10. A use according to any one of Claims 1 to 4, wherein the medicament is for treatment of acute myocardial infarction, ischemic stroke, deep venous thrombosis or pulmonary embolism.

30 11. A use according to any one of Claims 1 to 4, wherein the medicament is for dissolving a clot occurring with a chronically implanted medical device.

12. A use according to any one of the preceding claims, wherein the catheter delivery means comprises a "side hole" catheter device.

35 13. A use according to any one of Claims 1 to 11, wherein the catheter delivery means comprises a "pressure response outlet" (PRO) catheter delivery device.

40 14. A use according to Claim 13, wherein the solution of fibrinolytic metalloproteinase is for administration by pulse-spray infusion.

15. A use according to Claim 14, wherein the fibrinolytic metalloproteinase solution is for administration in a pulse volume of from about 0.1 to about 0.5 millilitre of fibrinolytic metalloproteinase solution per pulse.

45 16. A use according to any one of Claims 1 to 15, wherein the fibrinolytic metalloproteinase is present at a concentration in the range from about 0.1 to about 80 milligrams per millilitre.

17. A use according to any one of the preceding claims, wherein the fibrinolytic metalloproteinase is Novel Acting Thrombolytic (NAT).

50 18. A use according to any one of Claims 1 to 16, wherein the fibrinolytic metalloproteinase is fibrolase.

**55 Patentansprüche**

1. Verwendung einer fibrinolytischen Metalloproteinase, die mit  $\alpha_2$ -Makroglobulin komplexiert, in einer pharmazeutisch annehmbaren Lösung zur Herstellung eines Arzneimittels zur therapeutischen Behandlung, in einem menschlichen

chen Patienten, eines Blutgerinnsels durch lokale Verabreichung zum Blutgerinnsel durch Katheterzuführungs-  
mittel, wobei die fibrinolytische Metallproteinase zur Verabreichung in einer Menge ist, die zwischen 0,025 und  
1,7 Milligramm der fibrinolytischen Metallproteinase pro Kilogramm Körpergewicht des zu behandelnden mensch-  
lichen Patienten schwankt.

5        2. Verwendung nach Anspruch 1, **dadurch gekennzeichnet, daß** die Menge der fibrinolytischen Metallproteinase  
im Bereich von etwa 0,1 bis etwa 0,5 Milligramm pro Kilogramm Körpergewicht ist.

10      3. Verwendung nach Anspruch 1 oder 2, **dadurch gekennzeichnet, daß** die fibrinolytische Metallproteinase zur  
Zuführung über Intrathrombus-Verabreichung ist,

15      4. Verwendung nach einem der Ansprüche 1 bis 3, **dadurch gekennzeichnet, daß** die fibrinolytische Metallproteinase  
zur Verabreichung in der engen Nachbarschaft des Blutgerinnsels ist.

20      5. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** das Blutgerinnsel in einer Arterie  
lokalisiert ist.

25      6. Verwendung nach Anspruch 5, **dadurch gekennzeichnet, daß** das Arzneimittel zur Behandlung peripherer Arte-  
rienokklusion ist.

30      7. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** das Blutgerinnsel in einer Vene  
lokalisiert ist.

35      8. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** der menschliche Patient periphere  
Gefäßkrankung hat.

40      9. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** die periphere Gefäßkrankung  
auf Atherosklerose beruht.

45      10. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** das Arzneimittel zur Behandlung  
von akutem Myocardinfarkt, ischämischem Schlaganfall, tiefer Venenthrombose oder Lungenembolie ist.

50      11. Verwendung nach einem der Ansprüche 1 bis 4, **dadurch gekennzeichnet, daß** das Arzneimittel zum Auflösen  
eines Gerinnsels ist, das mit einer chronisch implantierten medizinischen Einheit auftritt.

55      12. Verwendung nach einem der vorangehenden Ansprüche, **dadurch gekennzeichnet, daß** das Katheterzufüh-  
rungsmittel eine "Seitenloch"-Kathetervorrichtung umfaßt.

60      13. Verwendung nach einem der Ansprüche 1 bis 11, **dadurch gekennzeichnet, daß** das Katheterzuführungsmittel  
eine Katheterzuführungsvorrichtung mit "druckreaktivem Auslaß" (PRO) umfaßt.

65      14. Verwendung nach Anspruch 13, **dadurch gekennzeichnet, daß** die Lösung der fibrinolytischen Metallproteinase  
zur Verabreichung durch Puls-Sprühinfusion ist.

70      15. Verwendung nach Anspruch 14, **dadurch gekennzeichnet, daß** die fibrinolytischen Metallproteinaselösung zur  
Verabreichung in einem Pulsvolumen von etwa 0,1 bis etwa 0,5 Milliliter fibrinolytischer Metallproteinaselösung  
pro Puls ist.

75      16. Verwendung nach einem der Ansprüche 1 bis 15, **dadurch gekennzeichnet, daß** die fibrinolytische Metallpro-  
teinase in einer Konzentration im Bereich von etwa 0,1 bis etwa 80 Milligramm pro Milliliter vorliegt.

80      17. Verwendung nach einem der vorangehenden Ansprüche, **dadurch gekennzeichnet, daß** die fibrinolytische Me-  
tallproteinase Novel Acting Thrombolytic (NAT) ist.

85      18. Verwendung nach einem der Ansprüche 1 bis 16, **dadurch gekennzeichnet, daß** die fibrinolytische Metallpro-  
teinase Fibrolase ist.

**Revendications**

1. Utilisation d'une métalloprotéinase fibrinolytique qui forme un complexe avec une macroglobuline alpha-deux dans une solution pharmaceutiquement acceptable pour la fabrication d'un médicament pour le traitement thérapeutique chez un sujet humain d'un caillot sanguin par administration locale vers le caillot sanguin par des moyens de délivrance par cathéter, dans laquelle la métalloprotéinase fibrinolytique est administrée dans une quantité se trouvant dans la plage entre 0,025 et 1,7 milligramme de la métalloprotéinase fibrinolytique par kilogramme de poids corporel du sujet humain à traiter.
2. Utilisation selon la revendication 1, dans laquelle la quantité de la métalloprotéinase fibrinolytique se trouve dans la plage d'environ 0,1 à environ 0,5 milligramme par kilogramme de poids corporel.
3. Utilisation selon la revendication 1 ou 2, dans laquelle la métalloprotéinase fibrinolytique est délivrée via administration intrathrombus.
4. Utilisation selon une quelconque des revendications 1 à 3, dans laquelle la métalloprotéinase fibrinolytique est administrée dans le proche voisinage du caillot sanguin.
5. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle le caillot sanguin est situé dans une artère.
6. Utilisation selon la revendication 5, dans laquelle le médicament est destiné au traitement d'occlusion artérielle périphérique.
7. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle le caillot sanguin est situé dans une veine.
8. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle le sujet humain a une maladie vasculaire périphérique.
9. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle la maladie vasculaire périphérique est due à l'athérosclérose.
10. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle le médicament est destiné au traitement de l'infarctus du myocarde aigu, l'accident vasculaire cérébral ischémique, la thrombose veineuse profonde ou l'embolie pulmonaire.
11. Utilisation selon une quelconque des revendications 1 à 4, dans laquelle le médicament est destiné à dissoudre un caillot se produisant avec un dispositif médical implanté de façon chronique.
12. Utilisation selon une quelconque des revendications précédentes, dans laquelle les moyens de délivrance du cathéter comprennent un dispositif de cathéter à "trou latéral".
13. Utilisation selon une quelconque des revendications 1 à 11, dans laquelle les moyens de délivrance du cathéter comprennent un dispositif de délivrance du cathéter à "sortie fonction de la pression" (PRO).
14. Utilisation selon la revendication 13, dans laquelle la solution de métalloprotéinase fibrinolytique est administrée par perfusion par pulvérisation - impulsion.
15. Utilisation selon la revendication 14, dans laquelle la solution de métalloprotéinase fibrinolytique est administrée dans un volume par impulsion d'environ 0,1 à environ 0,5 millilitre de solution de métalloprotéinase fibrinolytique par impulsion.
16. Utilisation selon une quelconque des revendications 1 à 15, dans laquelle la métalloprotéinase fibrinolytique est présente à une concentration dans la plage d'environ 0,1 à environ 80 milligrammes par millilitre.
17. Utilisation selon une quelconque des revendications précédentes, dans laquelle la métalloprotéinase fibrinolytique est un nouvel agent ou acteur thrombolytique (NAT).
18. Utilisation selon une quelconque des revendications 1 à 18, dans laquelle la métalloprotéinase fibrinolytique est

la fibrolase.

5

10

15

20

25

30

35

40

45

50

55

FIGURE 1A




FIGURE 1B



FIGURE 1C




FIGURE 2




FIGURE 3

